Stocks · News reference
Amylyx Pharmaceuticals To Announce Phase 3 LUCIDITY Trial Topline Results For Avexitide In Post-Bariatric Hypoglycemia On August 18 At 8:00 a.m. ET
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18,
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 8:01 PM
- Checked
- Aug 17, 2026, 8:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Benzinga Bulls and Bears: Ross, Moderna, Webull
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Read original at benzinga8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)
Filed: 2026-08-20 AccNo: 0001193125-26-359418 Size: 411 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Read original at edgarReported Earlier, Amylyx Pharmaceuticals Prices Upsized $500M Public Offering Of 14,090,000 Common Shares At $35.50 Per Share
Read original at benzinga